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Abstract 
Background: We recently reported strong associations between eight skin collagen AGEs and two solubility markers 
from skin biopsies obtained at DCCT study closeout and the long-term progression of microvascular disease in EDIC, 
despite adjustment for mean glycemia. Herein we investigated the hypothesis that some of these AGEs (fluorescence 
to be reported elsewhere) correlate with long-term subclinical cardiovascular disease (CVD) measurements, i.e. coro-
nary artery calcium score (CAC) at EDIC year 7–9 (n = 187), change of carotid intima-media thickness (IMT) from EDIC 
year 1 to year 6 and 12 (n = 127), and cardiac MRI outcomes at EDIC year 15–16 (n = 142).
Methods: Skin collagen AGE measurements obtained from stored specimens were related to clinical data from the 
DCCT/EDIC using Spearman correlations and multivariable logistic regression analyses.
Results: Spearman correlations showed furosine (early glycation) was associated with future mean CAC (p < 0.05) 
and CAC >0 (p = 0.039), but not with CAC score <100 vs. >100. Glucosepane and pentosidine crosslinks, methylg-
lyoxal hydroimidazolones (MG-H1) and pepsin solubility (inversely) correlated with IMT change from year 1 to 6(all 
P < 0.05). Left ventricular (LV) mass (cMRI) correlated with MG-H1, and inversely with pepsin solubility (both p < 0.05), 
while the ratio LV mass/end diastolic volume correlated with furosine and MG-H1 (both p < 0.05), and highly with 
CML (p < 0.01). In multivariate analysis only furosine (p = 0.01) was associated with CAC. In contrast IMT was inversely 
associated with lower collagen pepsin solubility and positively with glucosepane,
Conclusions: In type 1 diabetes, multiple AGEs are associated with IMT progression in spite of adjustment for A1c 
implying a likely participatory role of glycation and AGE mediated crosslinking on matrix accumulation in coronary 
arteries. This may also apply to functional cardiac MRI outcomes, especially left ventricular mass. In contrast, early 
glycation measured by furosine, but not AGEs, was associated with CAC score, implying hyperglycemia as a risk factor 
in calcium deposition perhaps via processes independent of glycation.
Trial registration: Registered at Clinical trial reg. nos. NCT00360815 and NCT00360893, http://www.clinicaltrials.gov
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Background
Patients with type 1 diabetes (T1DM) have a high risk of 
developing cardiovascular disease (CVD). The Diabetes 
Control and Complication Trial (DCCT)/Epidemiology 
of Diabetes Interventions and Complications (EDIC) has 
examined the impact of intensive glycemic treatment on 
the progression of subclinical CVD events in multiple 
studies. The findings indicate that coronary artery cal-
cium deposition (CAC >) at EDIC year 7–9 was signifi-
cantly lower in the intensive vs. conventional treatment 
group in the primary prevention but not secondary retin-
opathy intervention cohort. Waist to hip ratio, smok-
ing, hypertension and hypercholesterolemia and HbA1c 
during DCCT and EDIC were also associated with the 
presence of CAC. Progression of carotid intima media 
thickness (IMT) at year 6 was significantly greater in the 
T1DM patients than in gender and age-matched controls 
and progression from EDIC year 1 to 6 was also lowered 
by intensive therapy. IMT was also associated with age, 
systolic blood pressure at EDIC onset, smoking, the LDL/
HDL ratio, the urinary albumin excretion rate and mean 
HbA1c during the DCCT [1]. Finally, cardiac MRI stud-
ies performed at EDIC year 13–15 showed that greater 
left ventricular (LV) mass was associated with mean SBP, 
smoking and macroalbuminuria but not mean HbA1c 
over the entire preceding DCCT and EDIC period [2]. 
Mean A1c was however associated with the ratio of LV 
mass/EDV.
From another perspective, our previous research on 
the ability of skin advanced glycation products to pre-
dict complication progression in the DCCT/EDIC 
revealed a strong association between degree of skin 
collagen insolubilization and modifications by advanced 
glycation endproducts with the long-term progres-
sion rate and severity of microvascular disease [3–5]. In 
particular, addition of four skin collagen linked AGEs 
(i.e. glucosepane, carboxyethyl-lysine(CEL), methylg-
lyoxal hydroimidazolone (MG-H1) and glyoxal hydro-
imidazolone (G-H1) to the original set of glycation 
products comprising furosine (glycated lysine a.k.a. 
fructose-lysine), carboxymethyl-lysine (CML), pento-
sidine, collagen fluorescence and collagen insolubility 
parameters significantly enhanced the strength of asso-
ciation between AGEs and the risk of progression over 
13–16  years of microvascular and neuropathic compli-
cations during EDIC [6]. Multivariate logistic regression 
analysis showed that the glycation products glucosepane 
and furosine were most strongly associated with the risk 
of progression of retinopathy, furosine with nephropathy, 
and MG-H1 and furosine with clinical neuropathy. Most 
notably, adjustment for mean glycemia during the DCCT 
and EDIC did not impact on these associations, possibly 
implying a pathogenetic role of matrix bound AGEs for 
complications.
Based on the above findings we now investigated the 
association between the above skin glycation products 
and the progression of subclinical cardiovascular dis-
ease, namely coronary calcium deposition, carotid intima 
thickening and various parameters of diabetic cardiomy-
opathy in the same subset of the DCCT/EDIC cohort.
Methods
Subjects and outcomes
216 participants in the DCCT study from 8 clinics origi-
nally volunteered for a skin biopsy 1–2  years prior to 
DCCT closeout in 1993, as previously described [3]. Of 
these, 123 were from the primary cohort (1–5 years dia-
betes duration and no retinopathy on fundus photogra-
phy) and 93 were in the secondary cohort (1–15  years 
diabetes duration and at least one retinal microaneurysm 
on fundus photography). Data on Coronary Artery Cal-
cium (CAC) deposition measured by CT at EDIC years 
7–9 [7] were available in 187 of those originally biopsied. 
Data on carotid intima–media thickness (IMT) meas-
ured by ultrasonography at EDIC year 6 and 12 [1] were 
available in 127 participants. The maximal IMT of the 
common carotid artery was defined as the mean of the 
maximal value for the near and far walls on both the right 
and left sides [1]. Cardiac magnetic resonance imaging 
(CMRI) measures were obtained in EDIC years 14–16 in 
142 of the skin biopsy donors including left ventricular 
(LV) mass, (EDV) and end-systolic volume (ESV), stroke 
volume (SV), cardiac output (CO), ejection fraction (EF) 
and LV mass/EDV.
Advanced glycation products (AGEs) in skin biopsies
Two skin biopsies were originally obtained at DCCT clo-
seout in 1993, one of which was immediately processed 
for the measurement of 6 collagen solubility and glyca-
tion products, i.e. acid and pepsin solubility of collagen, 
collagen-linked fluorescence at 375 and 440  nm, furo-
sine (acid conversion product of fructose-lysine) and the 
AGEs carboxymethyl-lysine (CML) and pentosidine, as 
described [3]. The second biopsy was stored under argon 
at −80  °C and processed in 2012 using enzymatic pro-
teolysis to release the acid labile products including the 
AGE crosslink glucosepane together with those derived 
from the oxoaldehydes methylgloxal (MG-H1) and gly-
oxal (G-H1). These were assayed by liquid chromatogra-
phy mass spectrometry as previously described [6]. The 
acid stable carboxyethyl-lysine (CEL) was included in this 
panel. Thus, analyses assessed the association of these 
nine markers with subclinical measures of macrovascular 
disease, whereby findings on collagen-linked fluorescence 
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will be reported in a subsequent study addressing the 
molecular nature of fluorescence in type 1 diabetes.
Statistical methods
Univariate differences between groups were assessed 
using Wilcoxon rank-sum test for quantitative or ordinal 
variables and Chi square test for categorical variables. 
Spearman correlations evaluated the association of skin 
collagen variables with other outcomes when adjusted for 
age and diabetes duration.
Since the level of CAC was not measurable for the 
majority of subjects, the associations with the quantita-
tive levels of CAC were assessed using a Tobit regres-
sion model [8]. Associations with the quantitative levels 
of IMT and cMRI measures were assessed using normal 
errors linear models, that for IMT using an unstructured 
covariance structure [9].
Multivariable logistic regression models were assessed 
for the association of skin collagen AGE variables with 
the odds of abnormal levels of pre-clinical macrovascu-
lar measures. Significance of effects of specific covariate 
blocks, adjusted for other covariates, was evaluated using 
a likelihood ratio test (LRT) [10]. Backward elimination 
was used starting with all 10 AGEs (the original and 
new sets combined, including fluorescence) to select the 
subset of skin collagen variables nominally significantly 
associated with risk of complications at the 0.05 signifi-
cance level. Entropy R2 was used to assess the strength of 
association in logistic regression models [10]. Odds ratio 
per standard deviation increase in the skin collagen AGE 
variables and HbA1c were reported. For univariate AGE 
effects, Benjamini and Hochberg’s false discovery rate 
(FDR) alpha adjustment for multiple tests was conducted 
to control the overall FDR at a level of 0.05 [11]. Unless 
otherwise noted, nominal p-values were presented. SAS 
software was used to perform these analyses.
Results
Clinical characteristics of participants
DCCT baseline characteristics of the 216 participants 
from the primary and secondary cohorts are summa-
rized in Table  1. By design, the secondary cohort had 
longer diabetes duration and more advanced retinopathy 
[12]. The data show that it also had higher triglycerides 
and cholesterol, thicker intima media layers, higher CAC 
scores, but was not different in terms of cardiac subclini-
cal endpoints (Table 2).
Coronary artery calcium deposition
Of the 216 originally biopsied participants, 187 under-
went computed tomography for measurement of CAC 
deposition analysis during EDIC years 7–9. Spear-
man correlation analysis reveals that furosine, i.e. the 
glucose-derived Amadori product significantly correlates 
with severity of coronary artery calcium deposition, both 
as quantitative variable (p = 0.026) as well as for the cat-
egorical comparison CAC >0 vs CAC =  0 (p =  0.039), 
though the effect was not significant for CAC >100 
(Table 3).
Multivariate regression analysis (Table  4) confirmed 
the association between quantitative CAC score with 
furosine and showed that it was weakened upon adjust-
ment for DCCT mean A1c but not for EDIC mean A1c. 
Multivariate analysis also confirmed the Spearman corre-
lation data showing that furosine was not associated with 
higher CAC scores (not shown). In contrast, the associa-
tion between quantitative CAC score or CAC score >0 
with DCCT mean A1c (p  =  0.025; p  =  0.031, respec-
tively) became non-significant upon adjustment for 
furosine (Table  4), perhaps suggesting that at the tissue 
level is a more relevant risk factor than at the blood level. 
EDIC mean A1c was not associated with CAC score.
Table 1 Clinical characteristics of  skin donors at  DCCT 
baseline and mean AGE levels at time of DCCT biopsy
Primary Secondary P value
N = 216 123 93
DCCT baseline
 Female (%) 53 % 41 %
 Age (years) 27.1 (6.8) 29.6 (6.5) 0.009
 Duration (months) 2.7 (1.4) 8.6 (4) <0.001
 HbA1c (%) (mmol/mol) 9.1 (1.8) 8.9 (1.5)
 Mean blood glucose (mg/dl) 230.4 (82.8) 225.6 (71.5)
 Triglycerides (mg/dl) 72.4 (50.5) 92.9 (51.6) <0.001
 Cholesterol (mg/dl) 178.3 (32.7) 179.1 (36.5) 0.006
 Retinopathy (%)
  10/10: None 100 0
  20/≤20: Microaneurysms only 0 60
  30/≤30: Mild NPDR 0 28
  45/≤45: Moderate NPDR 0 11
 AER >40 mg/24 h 1 10 0.003
 Confirmed clinical neuropathy (%) 3 14 0.004
 sBP (mmHg) 114.7 (11.9) 119.4 (10.5)
 dBP (mmHg) 72.9 (8.5) 75.1 (7.8)
AGEs and solubility parameters
 Acid soluble (%) 0.5 (0.3) 0.6 (0.4)
 CEL (pmol/mg collagen) 141.4 (104) 152.5 (111.1)
 CML (pmol/mg collagen) 527.8 (140.4) 548.1 (119.2)
 Furosine (pmol/mg collagen) 756.2 (239.9) 786.2 (219.8)
 G-H1 (pmol/mg collagen) 66.8 (30.7) 63.6 (38)
 GSPNE (nmol/mg collagen) 2.5 (0.6) 2.6 (0.7)
 MG-H1 (nmol/mg collagen) 0.8 (0.4) 0.8 (0.5)
 Pentosidine (pmol/mg collagen) 25.3 (6.2) 26.6 (8.6)
 Pepsin Soluble (%) 6.8 (3.5) 6.5 (3)
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Intima media thickness (IMT)
Data were available in 127 participants. Spearman corre-
lation analysis (Table  3) showed that the progression of 
IMT between EDIC year 1 and 6 was positively associ-
ated with pentosidine, methylglyoxal hydroimidazolone 
and glucosepane, but inversely associated with collagen 
pepsin solubility (all p values <0.05). Multivariate regres-
sion analysis (Table 5) confirmed these associations and 
revealed that adjustment for DCCT and EDIC mean A1c 
did not abolish the association with MG-H1 and pento-
sidine, though GSPN became non-significant. Collagen 
solubility by pepsin was inversely associated with IMT 
(p = 0.048) and the association was abolished by adjust-
ment with mean A1c. Mean DCCT and EDIC A1c were 
not associated with IMT in this skin biopsy cohort, 
although DCCT mean A1c was associated with IMT in 
the complete DCCT cohort [1]. Most of the associations 
between the collagen modification and IMT vanished 
beyond year 6.
Leftventricular thickness and other cardiac functional 
parameters (cMRI)
Among the various cardiac indices measured by cMRI 
between EDIC year 14 and 16, left ventricular mass (LV) 
was significantly associated with skin modifications, in 
particular furosine, pepsin solubility (inversely), and 
MG-H1 (Table  3). As for the entire DCCT cohort [2], 
mean A1c values were not associated with LV mass.
In summary, except for the early glycation product 
furosine  >  DCCT mean A1c, none of the AGEs were 
associated with CAC. Progression of IMT was most 
strongly associated with MG-H1~pentosidine>glucosepa
ne~pepsin insolubility based of the p values of the mul-
tivariate analysis. Finally, leftventricular mass was most 
strongly associated with MG-H1 and pepsin insolubility, 
while the LV mass over end diastolic volume ratio was 
most strongly associate with CML ≫  MG-H~furosine. 




In a recent study we have shown that expansion of the 
original set of 6–10 skin collagen AGEs and parameters 
of collagen solubility enhances the association between 
the skin markers of long-term glycemic damage and the 
progression of microvascular complications [5]. Notably 
the full set of all 10 AGE markers, including fluorescence, 
was associated with the risk of retinopathy, nephropa-
thy and neuropathy progression in spite of adjustments 
for mean DCCT and EDIC A1c. Collagen glycation, i.e. 
fructose-lysine measured as furosine acid conversion 
product, was most consistently associated with either 
past or future progression of all three microvascular 
complications in EDIC. Adjustment for DCCT A1c did 
not nullify these robust associations except for nephropa-
thy. Similarly, the associations between glucosepane and 
retinopathy, and MG-H1 with neuropathy were not nul-
lified by adjustment for DCCT A1c, respectively. Finally, 
the association between DCCT mean A1c and each 
microvascular complication was nullified by adjustment 
for AGEs, as a group or individually. The above results 
raised the compelling question of the extent to which 
skin AGEs measured up to 19 years prior to assessment 
of subclinical indicators of macrovascular disease were 
also associated with their progression in type 1 diabetes, 
and whether specific AGEs were associated with specific 
subclinical macrovascular disease.
Associations between early glycation, advanced glycation 
and CAC deposition
In this study, only furosine (early glycation) and mean 
DCCT A1c were associated with CAC. This latter asso-
ciation was nullified upon adjustment for furosine indi-
cating a close relationship between glycemia at the tissue 
level and the process leading to calcium deposition in 
the coronary arteries of individuals with type 1 diabe-
tes. In view of the fact that none of the specific advanced 
glycation end products predicted this association, it 
is difficult to envisage a direct mechanistic role in this 
process. However, van Eupen et  al., found that plasma 
AGEs are associated with CAC deposition [13]. In that 
regard CML was found to accelerate calcification in dia-
betic rat, possibly by engaging RAGE in macrophages 
Table 2 Subclinical cardiovascular outcomes of  the skin 
biopsy study participants during EDIC
Primary Secondary P value
Intima-media thickening study (N = 127)
 EDIC year 1 6 (0.7) 6.2 (0.8)
 EDIC year 6 6.2 (0.8) 6.5 (0.8) 0.003
 EDIC year 12 6.8 (0.9) 7.1 (1.1)
Coronary calcium study (N = 187)
 CAC Mean (Agatston units) 23 (109.2) 91.7 (281) 0.002
Cardiac MRI studies (N = 142)
 Left ventricular end diastolic 
mass (g)
146.6 (33.2) 149.6 (35.8)
 End diastolic volume (ml) 144.1 (34.4) 140.6 (31.6)
 End systolic volume (ml) 56.5 (16.3) 55.4 (17.7)
 Stroke volume (ml) 87.5 (21.7) 85.2 (19.4)
 Cardiac output (L/min) 6 (1.5) 5.9 (1.3)
 Ejection fraction (%) 60.8 (5) 61 (6.9)
 LV mass/end diastolic  
volume (g/ml)
1 (0.2) 1.1 (0.2)
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and induction of the BMP-2-cbfα1-ALP-calcification 
cascade [14]. However, since the association uncovered 
by van Eupen et al. was preferentially with pentosidine, a 
marker of increased ascorbic acid oxidation [15], a more 
likely explanation is that CAC is accelerated by hyper-
glycemia mediated oxidant stress and NADPH oxidase 
activity which triggers BMP activation and calcium dep-
osition [15].
Possibly implicating indirect effects in which CML-rich 
proteins e.g. stimulate BMP deposition [16] into the arte-
rial wall.
Association with intima‑media thickness
In contrast to coronary artery calcium deposition, a 
causal relationship between IMT and glycation is strongly 
suggested from the observation that IMT is associated 
with multiple AGE crosslinks, such as glucosepane and 
pentosidine, as well as methylglyoxal hydroimidazolone 
MG-H1. Methylglyoxal itself is a source of methylg-
lyoxal-derived imidazole (MODIC) crosslinks which, 
although not measured here, are also elevated in skin 
collagen from diabetic individuals [17]. Together, these 
three arginine-lysine AGE crosslinks may participate in 
Table 3 Associations of AGEs with sub-clinical cardiovascular disease outcomes
Italic values indicate statistically significant associations
* p < 0.05, ** p < 0.01.
^ Analyses of correlations and their associated p values used Spearman correlations.
+ P values between categorical results were generated using the Wilcoxon two sample test.
# Numbers in parentheses are the Benjamini and Hochberg’s FDR alpha adjustment.
N Furosine CML Pentosidine Pepsin soluble Acid soluble CEL G‑H1 MG‑H1 Glucosepane
Coronary artery calcification
CAC score (correlation 
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P Value (FDR)+,# 0.039 0.13 0.15 0.76 0.32 0.22 0.12 0.7 0.32
CAC score <100 vs. 






































P-Value (FDR)+,# 0.32 0.25 0.38 0.27 0.73 0.87 0.49 0.29 0.65
Common IMT (correlation)
 Year 6 127 0.17 0.14 0.13 −0.11 0.02 0.10 −0.06 0.21* 0.19*




















 Year 12 127 0.15 0.06 −0.04 0.00 0.02 0.05 −0.02 0.06 0.16
 Change: year  
12–year 1
127 0.07 0.06 0.02 −0.13 −0.05 0.03 0.10 0.01 0.15
Cardiac MRI studies


















 End diastolic  
volume (ml)
142 −0.05 −0.02 0.09 −0.10 −0.10 0.06 −0.12 0.00 −0.07
 End systolic  
volume (ml)
142 −0.06 −0.02 0.07 −0.07 0.00 0.07 −0.06 0.01 −0.09
 Stroke volume (ml) 142 −0.03 −0.03 0.07 −0.07 −0.12 0.04 −0.10 −0.03 −0.03
 Cardiac (L/min) 142 0.14 0.02 0.06 −0.08 −0.08 0.01 −0.01 −0.08 0.05
 Ejection fraction (%) 142 0.02 −0.05 −0.07 0.05 −0.07 −0.02 −0.04 −0.04 0.01
 LV mass/end  
diastolic volume 
(g/ml)
142 0.18* 0.22** 0.08 −0.13 −0.13 −0.05 0.09 0.19* 0.15
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decreasing collagen solubility, explaining the significant 
inverse relationship noted between pepsin solubility and 
IMT change between year 1 and 6. A role for glucosepane 
crosslinks in this process is strongly supported by the 
observation that glucosepane is the single major AGE 
and crosslink in skin collagen from individuals with dia-
betes [17]. Moreover, the Oslo Diabetes Study recently 
reported similar associations between skin glucosepane 
and both IMT and pulse wave velocity in 27 participants 
with type 1 diabetes of very long duration [18].
Somewhat puzzling is that the association between 
AGEs and IMT became non-significant at year 12, 
though both furosine and glucosepane were borderline 
significant reinforcing the potential role of matrix 
crosslinking in IMT. One explanation is the contribution 
of lipid abnormalities became with time less important 
as determinant of IMT progression as that the number 
of participants on statins increased from 2.94 to 13.2 
and 49 % at EDIC year 1, 6 and 12, respectively. In addi-
tion, glycemia improved in the control group with mean 
A1c values decreasing concomitantly from 8.9 to 8.6 and 
8.3  %, respectively. These two metabolic effects likely 
altered either the IMT progression rate and/or the colla-
gen turnover rate, resulting in weakened ability for skin 
AGEs to predict the very long-term IMT progression 
rate.
Table 4 Multivariable regressions of AGE effect on CT calcification outcomes (N = 187)
Italic values indicate statistically significant associations
* Models for CAC mean score were based on a Tobit-censored regression which evaluated the effect of AGE or HbA1c on the outcome of log (CT score)-log (lowest 
detectable CT score) allowing for unmeasurable values below the lower limit of quantification. Both unadjusted and adjusted models were adjusted for scanning site, 
baseline age, diabetes duration, sex, and DCCT baseline retinopathy cohort (primary vs. secondary). Adjusted models further included both AGE and HbA1c as risk 
factors.
** Models for CAC >0 and CAC >100 were based on a Generalized Linear Mixed Model (GLIMMIX) logistic regression which evaluated the effect of AGE or HbA1c on 
the prevalence of CAC >0 or CAC >100. Both unadjusted and adjusted models were adjusted for baseline age, diabetes duration, sex, and DCCT baseline retinopathy 
cohort (primary vs. secondary) with scanning site as a random effect. Adjusted models further included both AGE and HbA1c as risk factors
^ Geometric mean ratio of CAC scores was the ratio of predicted CAC scores for a one unit increase in HbA1c.
# Odds ratio was the ratio of odds for CAC > 0 or CAC > 100 based on a one unit increase in HbA1c.
CAC score (quantitative)*
Covariate effects from multiple models X2 P value Geometric mean ratio (95 % CI)^
Furosine:
 Unadjusted for A1c 5.7 0.017 5.6 (1.4, 22.7)
 Adjusted for
  DCCT mean A1c 1.3 0.26 3.8 (0.4, 37.3)
  EDIC mean A1c 4.4 0.035 5.0 (1.1, 22.2)
DCCT mean A1c:
 Unadjusted 5.0 0.025 1.9 (1.1, 3.3)
 Adjusted for
  Furosine 0.2 0.68 1.2 (0.5, 3.0)
EDIC mean A1c:
 Unadjusted 0.6 0.52 1.1 (0.7, 1.8)
CAC >0**
Covariate effects from multiple models t value P value Odds ratio (95 % CI)#
DCCT mean A1c:
 Unadjusted 2.2 0.031 1.3 (1.0, 1.6)
EDIC mean A1c:
 Unadjusted 0.8 0.41 1.1 (0.9, 1.5)
CAC >100**
Covariate effects from multiple models t value P value Odds ratio (95 % CI)#
DCCT mean A1c:
 Unadjusted 0.4 0.68 1.1 (0.7, 1.6)
EDIC mean A1c:
 Unadjusted 0 0.71 1.1 (0.6, 2.0)
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Association with left ventricular mass and LV mass/end 
diastolic volume ratio
A similar relationship between collagen solubility and 
LV mass was observed, although neither furosine nor 
glucosepane were themselves associated with LV mass. 
This may suggest that cardiac hypertrophy is only indi-
rectly influenced by hyperglycemia, perhaps via methyl-
glyoxal levels, as suggested by the association between 
MG-H1 and LV mass. The observation that the ratio of 
LV mass/end diastolic volume was associated with furo-
sine and MG-H1, as well as the glycoxidation product 
CML, is surprising because CML was not associated with 
any of the other subclinical complications. In contrast, 
numerous studies showed that serum or plasma CML is 
strongly associated with cardiovascular disease in dia-
betes and aging [19–21]. The potential mechanism and 
implication of these findings is that CML formation from 
fructose-lysine could be catalyzed by Cu2+ [22]. Indeed 
Cu2+ chelation was shown to ameliorate diabetic cardio-
myopathy [23], thus supporting the proposed association 
between abnormal copper metabolism and diabetic car-
diomyopathy [24].
Potential role of methylglyoxal in subclinical CVD 
complications
The observation that MG-H1 is associated with IMT 
independently of glycemia, LV mass and LV mass/EDV 
raises the question of whether methylglyoxal plays a 
mechanistic role in the pathogenesis of atheroscle-
rotic complications. This proposition is supported by 
the lower levels of MG-H1 (and glucosepane!) in EDIC 
subjects with prior DCCT intensive control [5] and 
the findings of lower IMT levels in the intensive treat-
ment group of the whole DCCT/EDIC cohort [1]. A 
direct role for methylglyoxal lysine dimer (MOLD) 
[25] or MODIC [17] crosslinks has been alluded to, 
though these are present in amounts 100 times lower 
than glucosepane in skin from diabetic individuals 
[17]. Blocking of arginine residues by MG-H1 together 
with crosslinking might contribute to lowering colla-
gen turnover and thickening of the artery wall. Indeed 
Chong et  al. found the methylglyoxal modified colla-
gen binds less well phagocytes thought to play a role in 
collagen turnover [26]. However, there is also the pos-
sibility that higher methylglyoxal levels could stimu-
late collagen deposition. Several authors noted that 
cells incubated with methylglyoxal modified collagen 
induced collagen expression, TGF β1 expression [27] 
and promoted myofibroblast differentiation [28]. Meth-
ylglyoxal also exerts it’s toxicity by inhibiting cell bind-
ing to the modified matrix [29] resulting in anoikis [30]. 
Finally, a profibrotic effect was directly demonstrated 
when methylglyoxal given orally to mice lead to kidney 
collagen accumulation [31].
Finally, as noted above, this study’s findings parallel the 
recently observed glucosepane –IMT association in the 
Oslo study [18], and also the similar recent observation by 
the same investigators of an association between impaired 
left ventricular dysfunction, MG-H1 and glyoxal hydroim-
idazolone G-H1, with the caveat that MG-H1 was meas-
ured in the serum and G-H1 in skin [32]. Taken together, 
they raise the important question of whether a combina-
tion of glycation burden and altered cell signalling by the 
glycated extracellular matrix is the elusive mediator in the 
sclerotic process that underlies the pathogenesis of accel-
erated cardiovascular disease in diabetes.
Table 5 Multivariable regressions of  AGE effect on  IMT 
outcomes (N = 127)
Italic values indicate statistically significant associations
* Models were based on a general linear regression which evaluated the effect 
of respective AGE or HbA1c on the change of IMT from EDIC year 1 to year 6. 
Both unadjusted and adjusted models were adjusted for IMT levels at EDIC year 
1. Adjusted models further included both the respective AGE and HbA1c as risk 
factors.
^ LSMean difference was the difference of estimated Least Square mean of IMT 
change from EDIC year 1 to year 6 based on a one standard deviation increase 
in AGE (Pentosidine: 7.3, Pepsin soluble: 6.7, MG-H1: 0.44, GSPNE: 0.66: or a one 
unit increase in HbA1c.
IMT change from year 1 to year 6
Covariate effects  
from multiple models*
t value P value LSMean difference  
(95 % CI)^
MG-H1
 Unadjusted 2.6 0.012 0.01 (0.00, 0.02)
 Adjusted for
  DCCT mean A1c 2.5 0.014 0.01 (0.00, 0.02)
  EDIC mean A1c 2.7 0.008 0.01 (0.00, 0.02)
Pentosidine
 Unadjusted 2.4 0.016 0.01 (0.00, 0.03)
 Adjusted for
  DCCT mean A1c 2.4 0.020 0.02 (0.00, 0.03)
  EDIC mean A1c 2.3 0.022 0.01 (0.00, 0.03)
Glucosepane
 Unadjusted 2.0 0.048 0.01 (0.00, 0.02)
 Adjusted for
  DCCT mean A1c 0.7 0.48 0.00 (−0.01, 0.01)
  EDIC mean A1c −0.4 0.67 −0.00 (−0.01, 0.01)
Pepsin soluble
 Unadjusted −2.0 0.048 −0.03 (−0.06, -0.00)
 Adjusted for
  DCCT mean A1c −1.9 0.06 −0.03 (−0.07, 0.00)
  EDIC mean A1c −1.7 0.08 −0.03 (−0.06, 0.00)
DCCT mean A1c:
 Unadjusted 0.7 0.48 0.02 (−0.01, 0.01)
EDIC mean A1c:
 Unadjusted 1.5 0.14 0.05 (−0.00, 0.02)
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Limitations in the current study
The major limitation of our study is that the demonstrated 
associations between skin AGEs and subclinical CVD 
outcomes cannot prove a cause and effect relationship. 
Moreover, none of the many specific skin AGE molecules 
correlated consistently with any specific CAC, carotid 
IMT or CMRI outcome, undoubtedly reflecting the com-
plex pathogenesis of CVD in T1DM. Nonetheless, the 
false discovery rate was held to 0.05, minimizing the pos-
sibility that these are chance findings resulting from the 
multiple statistical tests that were conducted. Moreover, 
the positive association between plasma pentosidine and 
CAC has been found in T1DM [13] supports the proposi-
tion that AGEs are possibly involved in the development 
of CAC in individuals with T1DM. Similarly, specific 
AGE combinations, notably pentosidine and CEL, were 
strongly associated with micro- and macrovascular com-
plications in the Medalist Study [33]. Thus, these data 
are in keeping with the present study findings and rein-
force them, even though p values were not as strong as for 
microvascular disease outcomes [5]. Yet, in spite of these 
important findings, a major practical limitation is that 
biopsies for risk biomarker assessment are unlikely to be 
routinely implemented, and that therefore non-invasive 
methods will be needed to assay specific AGEs in skin.
Conclusions
These findings in a substantial DCCT/EDIC cohort add 
strong support to the premise that glycation of proteins 
and formation of crosslinks in the extracellular matrix likely 
plays a significant role in the pathogenesis of macrovascu-
lar complications in T1DM, especially what concerns the 
thickening of the carotid intima-media. Similar reasoning 
may apply to the enlargement of the left ventricle. However, 
coronary artery calcium deposition, while associated with 
collagen glycation per se, does not appear to be mediated 
by any specific matrix-linked AGEs. This latter conclusion 
might have to be revised in the future if a higher number of 
events helps uncover associations with specific AGEs.
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